Aura Biosciences, Inc. Common Stock
Symbol: AURA (NASDAQ)
6.18
▼ (-6.93%) -0.460
Company Description:
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Key Stats
- Today's Open: $6.67
- Today's High: $6.899
- Today's Low: $6.156
- Today's Volume: 193.97K
- Yesterday Close: $6.64
- Yesterday High: $6.67
- Yesterday Low: $6.4
- Yesterday Volume: 277.96K
- Last Min Volume: 11
- Last Min High: $6.18
- Last Min Low: $6.18
- Last Min VWAP: $6.18
Company Profile
- Name: Aura Biosciences, Inc. Common Stock
- Website: https://www.aurabiosciences.com
- Listed Date: 2021-10-29
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001501796
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $383.90M
- Round Lot: 100
- Outstanding Shares: 62.12M
- Asset Type: CS
RECENT FILINGS FOR AURA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-18 | 4 | View |
| 2025-08-18 | 144 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 8-K | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
| 2025-05-23 | SCHEDULE 13G | View |
| 2025-05-20 | 4 | View |
| 2025-05-20 | 4 | View |
| 2025-05-19 | SCHEDULE 13D/A | View |
| 2025-05-16 | 144 | View |
| 2025-05-16 | 3 | View |
| 2025-05-16 | 8-K | View |
Latest News on AURA